Aim: This prospective cohort study aimed to evaluate the impact of new antidiabetic agents on the incidence of cardiovascular (CV) events in patients with type 2 diabetes mellitus (T2DM), focusing on SGLT2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors. Materials and Methods:A total of 100 adult patients (aged ≥ 18 years) with T2DM were enrolled in the study, initiating therapy with one of the new antidiabetic agents. The study followed participants for 12 months, with assessments at baseline, 3, 6, and 12 months. The primary outcome was the occurrence of any major adverse cardiovascular event (MACE), while secondary outcomes included changes in glycemic control, body weight, blood pressure, and lipid profile. Results: The baseline characteristics of the study cohort were well-matched across treatment groups. Over the 12-month follow-up, the incidence of MACE was low and did not significantly differ between the three treatment groups (SGLT2i, GLP-1 RA, and DPP-4i). The mean reduction in HbA1c for the entire cohort was 1.5%, with SGLT2i showing the greatest reduction. Weight loss was also observed, with no significant differences between groups. Blood pressure and lipid profile changes were modest and similar across treatment arms. Age, baseline HbA1c, and systolic blood pressure were significant predictors of cardiovascular events. Conclusion: This study found no significant differences in cardiovascular events or metabolic changes among patients with T2DM treated with SGLT2 inhibitors, GLP-1 receptor agonists, or DPP-4 inhibitors over 12 months. Age, baseline HbA1c, and systolic blood pressure were identified as significant predictors of cardiovascular outcomes. Longer-term studies with larger sample sizes are needed to further assess the cardiovascular benefits of these newer antidiabetic agents.